CINECA IRIS Institutional Research Information System

DI DESIDERO, TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.242
EU - Europa 1.322
AS - Asia 436
AF - Africa 71
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
AN - Antartide 1
Totale 6.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.164
IT - Italia 409
SE - Svezia 282
CN - Cina 221
DE - Germania 154
BG - Bulgaria 153
GB - Regno Unito 98
CA - Canada 75
VN - Vietnam 72
UA - Ucraina 47
SG - Singapore 46
CI - Costa d'Avorio 45
TR - Turchia 43
FI - Finlandia 41
FR - Francia 38
AT - Austria 32
IN - India 24
BE - Belgio 20
HK - Hong Kong 16
CH - Svizzera 15
SN - Senegal 13
NG - Nigeria 11
RU - Federazione Russa 7
ES - Italia 6
NL - Olanda 6
AU - Australia 5
HU - Ungheria 3
ID - Indonesia 3
JP - Giappone 3
PL - Polonia 3
CZ - Repubblica Ceca 2
EG - Egitto 2
IE - Irlanda 2
NZ - Nuova Zelanda 2
RO - Romania 2
A1 - Anonimo 1
AM - Armenia 1
BR - Brasile 1
CL - Cile 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EU - Europa 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IL - Israele 1
IR - Iran 1
KR - Corea 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
PK - Pakistan 1
QA - Qatar 1
TW - Taiwan 1
Totale 6.083
Salva come PNG Salva come JPEG
Città #
Woodbridge 638
Fairfield 528
Ann Arbor 507
Chandler 339
Houston 328
Seattle 260
Ashburn 257
Cambridge 214
Wilmington 205
Serra 193
Sofia 153
Beijing 101
New York 101
Ottawa 71
Princeton 65
Lawrence 59
Des Moines 57
Dearborn 52
Medford 52
Abidjan 45
Dong Ket 38
Jacksonville 34
Nanjing 31
Vienna 31
Milan 28
Izmir 27
London 23
Marseille 22
San Diego 20
Brussels 19
Florence 19
Boulder 18
Nanchang 16
Düsseldorf 15
Falls Church 15
Frankfurt am Main 15
Pisa 15
Bremen 14
Hong Kong 14
Redwood City 14
Dakar 13
Istanbul 13
Lagos 11
Seacroft 11
Bern 10
Boardman 10
Lancaster 10
Hebei 9
Shenyang 9
Pune 8
Rome 8
Dülmen 7
Jiaxing 7
Kunming 7
Los Angeles 7
Phoenix 7
Rho 7
Auburn Hills 6
Norwalk 6
Ogden 6
Jüchen 5
Tappahannock 5
Baotou 4
Changsha 4
Guangzhou 4
Indiana 4
Nürnberg 4
Zhengzhou 4
Bromsgrove 3
Budapest 3
Chiswick 3
Groningen 3
Kilburn 3
Massa E Cozzile 3
Saronno 3
Shanghai 3
Walnut 3
Warsaw 3
Alessandria 2
Atlanta 2
Boston 2
Buffalo 2
Carugate 2
Central 2
Chengdu 2
Citta 2
Edinburgh 2
Gandhinagar 2
Genoa 2
Grimsby 2
Hangzhou 2
Jakarta 2
Jinan 2
Kocaeli 2
Lappeenranta 2
Lausanne 2
Madrid 2
Massa 2
Melbourne 2
Orange 2
Totale 4.933
Salva come PNG Salva come JPEG
Nome #
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 189
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 181
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 178
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 165
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 159
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 157
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 151
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 139
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 139
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 138
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 135
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 133
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 129
null 127
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 125
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 124
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 119
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 118
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 116
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 115
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 115
null 114
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 114
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 113
null 108
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 105
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 104
Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? 103
null 101
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 99
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 98
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 91
null 90
null 89
Prevention of capecitabine toxicity using a 5-FU test dose 88
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 83
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 83
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer 81
null 79
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 79
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 77
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 77
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. 76
null 76
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 76
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 75
Novel Pyrazolopyrimidine Derivatives as Therapeutic Agents for the Treatment of Medullary Thyroid Carcinoma 73
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. 73
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 72
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 67
Phase II clinical trial with pharmacokinetics (PK) and pharmacodynamics (PD) evaluation of metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): final clinical results 67
High frequency ultrasound and photoacoustic imaging for tissue characterization in vivo 64
Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation 62
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 61
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 60
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 59
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 51
null 48
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 43
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 40
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 35
Metronomic chemotherapy for triple negative breast cancer? 26
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 25
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 24
Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients 22
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 20
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth 18
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib 16
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer 13
Totale 6.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019322 0 0 0 0 0 0 0 0 0 0 181 141
2019/20201.551 150 91 117 152 142 172 177 137 164 107 115 27
2020/2021638 53 79 53 27 48 38 24 56 62 72 32 94
2021/2022676 12 45 12 34 130 102 13 28 37 29 36 198
2022/20231.014 118 141 84 93 111 125 6 79 186 6 57 8
2023/2024392 45 44 58 9 62 113 18 22 12 9 0 0
Totale 6.270